Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
Posted On Monday, June 02, 2025
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
Posted On Monday, June 02, 2025
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Posted On Monday, June 02, 2025
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Posted On Monday, June 02, 2025
FDA expands XENOVIEW® indication to include children from six years of age
Posted On Monday, June 02, 2025
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
Posted On Monday, June 02, 2025
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
Posted On Monday, June 02, 2025
TELA Bio Appoints Jeffrey Blizard as President
Posted On Monday, June 02, 2025
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
Posted On Monday, June 02, 2025
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Posted On Monday, June 02, 2025
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Posted On Monday, June 02, 2025
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
Posted On Monday, June 02, 2025
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Posted On Monday, June 02, 2025
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Posted On Monday, June 02, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Posted On Monday, June 02, 2025
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
Posted On Monday, June 02, 2025
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Posted On Monday, June 02, 2025
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Posted On Sunday, June 01, 2025
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Posted On Sunday, June 01, 2025
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Posted On Sunday, June 01, 2025
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted On Sunday, June 01, 2025
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
Posted On Sunday, June 01, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Posted On Saturday, May 31, 2025
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Posted On Saturday, May 31, 2025
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Posted On Saturday, May 31, 2025

Print